当前位置: X-MOL 学术Annu. Rev. Pharmacol. Toxicol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.
Annual Review of Pharmacology and Toxicology ( IF 11.2 ) Pub Date : 2018-08-22 , DOI: 10.1146/annurev-pharmtox-010818-021818
Jason H Karnes 1, 2, 3 , Matthew A Miller 1 , Katie D White 4 , Katherine C Konvinse 5, 6 , Rebecca K Pavlos 7, 8 , Alec J Redwood 8 , Jonathan G Peter 9, 10 , Rannakoe Lehloenya 9 , Simon A Mallal 4, 5, 8 , Elizabeth J Phillips 4, 5, 8
Affiliation  

Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen ( HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.

中文翻译:

免疫药物基因组学的应用:预测、预防和了解免疫介导的药物不良反应。

药物不良反应 (ADR) 是一项重大的医疗保健负担。免疫介导的药物不良反应 (IM-ADRs) 占 ADRs 的五分之一,但由于其严重性,造成了不成比例的高负担。人类白细胞抗原 (HLA) 基因的变异已成为预防先前不可预测的 IM-ADR 的潜在处方筛选策略。免疫药物基因组学结合了免疫基因组学和药物基因组学的学科,专注于免疫特异性变异对药物处置和 IM-ADR 的影响。在这篇综述中,我们介绍了 HLA 与 IM-ADRs 关联的最新证据,正在进行的 IM-ADRs 生物学机制研究,以及 IM-ADRs 临床可操作生物标志物的转化,重点是 T 细胞介导的 ADRs。
更新日期:2019-01-09
down
wechat
bug